Previous Close | 1.8100 |
Open | 1.8000 |
Bid | 0.0000 x 2200 |
Ask | 0.0000 x 2900 |
Day's Range | 1.7700 - 1.8900 |
52 Week Range | 0.9900 - 1.8900 |
Volume | |
Avg. Volume | 2,603,541 |
Market Cap | 702.051M |
Beta (5Y Monthly) | 0.99 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.3590 |
Earnings Date | Aug 15, 2022 - Aug 19, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for GERN
Novartis' (NVS) anti-PD-1 monoclonal antibody, tislelizumab, significantly extends median overall survival in first-line advanced esophageal cancer combined with chemotherapy.
FOSTER CITY, Calif., June 30, 2022--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced an amendment to expand its existing loan facility with Hercules Capital, Inc. (NYSE: HTGC) and Silicon Valley Bank, from up to $75 million to up to $125 million.
Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.